Citius Pharmaceuticals (NASDAQ:CTXR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at $0.05 EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Citius Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 15th.

Citius Pharmaceuticals Stock Performance

Shares of CTXR stock opened at $0.20 on Tuesday. The stock has a 50 day moving average price of $0.44 and a 200 day moving average price of $0.60. Citius Pharmaceuticals has a 52-week low of $0.19 and a 52-week high of $1.07. The firm has a market capitalization of $36.15 million, a P/E ratio of -1.34 and a beta of 1.66.

Institutional Investors Weigh In On Citius Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in shares of Citius Pharmaceuticals in the second quarter valued at about $29,000. BNP Paribas Financial Markets lifted its position in shares of Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares during the period. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals during the third quarter valued at approximately $47,000. Miller Investment Management LP increased its holdings in Citius Pharmaceuticals by 99.3% during the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in Citius Pharmaceuticals in the second quarter worth approximately $69,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.